SUS Stock Overview
Develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Regulatory Approvals For New Robotics Entrants Will Drive Demand For Simulation Products
My Notes
Capture your thoughts, links and company narrative
Surgical Science Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 159.20 |
| 52 Week High | SEK 192.40 |
| 52 Week Low | SEK 111.80 |
| Beta | 0.95 |
| 1 Month Change | -8.40% |
| 3 Month Change | 8.37% |
| 1 Year Change | 3.11% |
| 3 Year Change | -24.91% |
| 5 Year Change | 122.35% |
| Change since IPO | 1,284.35% |
Recent News & Updates
Recent updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Shareholder Returns
| SUS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -16.1% | -4.1% | -1.2% |
| 1Y | 3.1% | -1.4% | 12.2% |
Return vs Industry: SUS exceeded the Swedish Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: SUS underperformed the Swedish Market which returned 12.2% over the past year.
Price Volatility
| SUS volatility | |
|---|---|
| SUS Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: SUS has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SUS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 274 | Tom Englund | www.surgicalscience.com |
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room.
Surgical Science Sweden AB (publ) Fundamentals Summary
| SUS fundamental statistics | |
|---|---|
| Market cap | SEK 8.12b |
| Earnings (TTM) | SEK 131.65m |
| Revenue (TTM) | SEK 884.09m |
61.7x
P/E Ratio9.2x
P/S RatioIs SUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUS income statement (TTM) | |
|---|---|
| Revenue | SEK 884.09m |
| Cost of Revenue | SEK 286.19m |
| Gross Profit | SEK 597.90m |
| Other Expenses | SEK 466.25m |
| Earnings | SEK 131.65m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 14, 2025
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 67.63% |
| Net Profit Margin | 14.89% |
| Debt/Equity Ratio | 4.9% |
How did SUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/24 01:15 |
| End of Day Share Price | 2025/02/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surgical Science Sweden AB (publ) is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Jonsson | Berenberg |
| Viktor Högberg | Danske Bank |
| Jonatan Andersson | DNB Markets |